Click here for slides on this topic


Alirocumab

An injectable monoclonal antibody of the PCSK9 inhibitor class for the treatment of an inherited form of dyslipidemia called familial hypercholesterolemia (FH). Marketed as Praluent®.
The following content matched the glossary term: Alirocumab

Alirocumab Significantly Reduces LDL-C in High-Risk Patients in ODYSSEY FH I & FH II

Top

The PCSK9 inhibitor, alirocumab, significantly reduced LDL-C in high-risk patients with heterozygous FH in ODYSSEY FH I & FH II; from ESC 2015



Slide Library Results

Search Results for: Alirocumab Slides Found: 0